46. Malignant rheumatoid arthritis Clinical trials / Disease details

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05306353 (ClinicalTrials.gov)	May 15, 2023	23/3/2022	CD40L Antagonism in Rheumatoid Arthritis (RA)	Combining a CD40L-Binding Protein (VIB4920) With a TNF-alpha Inhibitor for the Treatment of Inadequately Controlled Rheumatoid Arthritis (ITN092AI)	Rheumatoid Arthritis	Drug: Placebo for VIB4920;Drug: VIB4920 with TNFi;Drug: VIB4920 without TNFi	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN)	Not yet recruiting	18 Years	70 Years	All	104	Phase 2	United States
2	NCT04163991 (ClinicalTrials.gov)	December 9, 2019	12/11/2019	A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: VIB4920;Drug: Placebo	Viela Bio	NULL	Completed	18 Years	99 Years	All	78	Phase 2	United States;Poland
3	NCT02780388 (ClinicalTrials.gov)	May 12, 2016	3/5/2016	A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis	A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis	Adult Onset Rheumatoid Arthritis	Drug: VIB4920;Other: Placebo	Viela Bio	NULL	Completed	18 Years	70 Years	All	57	Phase 1	United States;Poland